386 related articles for article (PubMed ID: 20799475)
1. Treatment with a combination of anti-IgE and specific immunotherapy for allergic rhinitis and asthma.
Hamelmann E; Rolinck-Werninghaus C; Wahn U; Kopp MV
Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess; 2009; 96():303-13; discussion 313-5. PubMed ID: 20799475
[TBL] [Abstract][Full Text] [Related]
2. The role of anti-IgE therapy in combination with allergen specific immunotherapy for seasonal allergic rhinitis.
Stock P; Rolinck-Werninghaus C; Wahn U; Hamelmann E
BioDrugs; 2007; 21(6):403-10. PubMed ID: 18020623
[TBL] [Abstract][Full Text] [Related]
3. Is there a role for anti-IgE in combination with specific allergen immunotherapy?
Hamelmann E; Rolinck-Werninghaus C; Wahn U
Curr Opin Allergy Clin Immunol; 2003 Dec; 3(6):501-10. PubMed ID: 14612676
[TBL] [Abstract][Full Text] [Related]
4. Role of immunmodulators in allergen-specific immunotherapy.
Kopp MV
Allergy; 2011 Jun; 66(6):792-7. PubMed ID: 21332502
[TBL] [Abstract][Full Text] [Related]
5. Anti-IgE for the treatment of allergic rhinitis--and eventually nasal polyps?
Verbruggen K; Van Cauwenberge P; Bachert C
Int Arch Allergy Immunol; 2009; 148(2):87-98. PubMed ID: 18799888
[TBL] [Abstract][Full Text] [Related]
6. [Anti-IGE therapy in asthma].
Mehiri Ben Rhouma N; Béji M; Louzir B; Daghfous J
Tunis Med; 2002 Oct; 80(10):575-80. PubMed ID: 12632749
[TBL] [Abstract][Full Text] [Related]
7. Anti-IgE therapy.
Brownell J; Casale TB
Immunol Allergy Clin North Am; 2004 Nov; 24(4):551-68, v. PubMed ID: 15474858
[TBL] [Abstract][Full Text] [Related]
8. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma.
Kopp MV; Hamelmann E; Zielen S; Kamin W; Bergmann KC; Sieder C; Stenglein S; Seyfried S; Wahn U;
Clin Exp Allergy; 2009 Feb; 39(2):271-9. PubMed ID: 19016798
[TBL] [Abstract][Full Text] [Related]
9. Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases.
Chang TW; Wu PC; Hsu CL; Hung AF
Adv Immunol; 2007; 93():63-119. PubMed ID: 17383539
[TBL] [Abstract][Full Text] [Related]
10. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.
Holgate ST; Djukanović R; Casale T; Bousquet J
Clin Exp Allergy; 2005 Apr; 35(4):408-16. PubMed ID: 15836747
[TBL] [Abstract][Full Text] [Related]
11. The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children.
Rolinck-Werninghaus C; Hamelmann E; Keil T; Kulig M; Koetz K; Gerstner B; Kuehr J; Zielen S; Schauer U; Kamin W; Von Berg A; Hammermann J; Weinkauf B; Weidinger G; Stenglein S; Wahn U;
Allergy; 2004 Sep; 59(9):973-9. PubMed ID: 15291906
[TBL] [Abstract][Full Text] [Related]
12. [The clinical significance of anti-IgE antibodies in the treatment of allergic rhinopathy].
Loidolt D; Vassella CC; de Weck AL; Stadler BM
Laryngorhinootologie; 1990 May; 69(5):255-9. PubMed ID: 2354019
[TBL] [Abstract][Full Text] [Related]
13. Omalizumab and the immune system: an overview of preclinical and clinical data.
Johansson SG; Haahtela T; O'Byrne PM
Ann Allergy Asthma Immunol; 2002 Aug; 89(2):132-8. PubMed ID: 12197568
[TBL] [Abstract][Full Text] [Related]
14. The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis.
Kopp MV; Brauburger J; Riedinger F; Beischer D; Ihorst G; Kamin W; Zielen S; Bez ; Friedrichs F; Von Berg A; Gerhold K; Hamelmann E; Hultsch ; Kuehr J
J Allergy Clin Immunol; 2002 Nov; 110(5):728-35. PubMed ID: 12417881
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of allergic diseases with monoclonal anti-IgE antibody].
Morita Y
Nihon Rinsho; 2001 Oct; 59(10):2019-22. PubMed ID: 11676148
[TBL] [Abstract][Full Text] [Related]
16. Anti-IgE in the treatment of allergic disorders in pediatrics.
Fried AJ; Oettgen HC
Curr Opin Pediatr; 2010 Dec; 22(6):758-64. PubMed ID: 20966754
[TBL] [Abstract][Full Text] [Related]
17. Omalizumab: a monoclonal anti-IgE antibody.
Belliveau PP
MedGenMed; 2005 Jan; 7(1):27. PubMed ID: 16369332
[TBL] [Abstract][Full Text] [Related]
18. Basophil allergen threshold sensitivity: a useful approach to anti-IgE treatment efficacy evaluation.
Nopp A; Johansson SG; Ankerst J; Bylin G; Cardell LO; Grönneberg R; Irander K; Palmqvist M; Oman H
Allergy; 2006 Mar; 61(3):298-302. PubMed ID: 16436137
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis.
Kuehr J; Brauburger J; Zielen S; Schauer U; Kamin W; Von Berg A; Leupold W; Bergmann KC; Rolinck-Werninghaus C; Gräve M; Hultsch T; Wahn U
J Allergy Clin Immunol; 2002 Feb; 109(2):274-80. PubMed ID: 11842297
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)- specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients.
Rossi RE; Monasterolo G
Int Arch Allergy Immunol; 2004 Sep; 135(1):44-53. PubMed ID: 15286445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
